Attached files

file filename
EX-99.1 - EX-99.1 - SCICLONE PHARMACEUTICALS INCd629293dex991.htm
EX-99.2 - EX-99.2 - SCICLONE PHARMACEUTICALS INCd629293dex992.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934.

Date of Report: November 12, 2013

(Date of earliest event reported)

 

 

SciClone Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   0-19825   94-3116852

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

950 Tower Lane, Suite 900, Foster City, CA   94404
(Address of principal executive offices)   (Zip Code)

(650) 358-3456

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02 Results of Operations and Financial Condition.

On November 12, 2013, SciClone Pharmaceuticals, Inc. issued a press release announcing final financial results for the third quarter ended September 30, 2013. The press release and a copy of the transcript of the conference call are attached hereto as Exhibit 99.1 and Exhibit 99.2 and are incorporated by reference herein in their entirety.

The information in Item 2.02 of this Current Report on Form 8-K/A, including Exhibits 99.1 and 99.2 to this Current Report on Form 8-K/A, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) The following exhibits are filed herewith:

Exhibit 99.1 Press release dated November 12, 2013.

Exhibit 99.2 Transcript of conference call dated November 12, 2013.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 14, 2013     SCICLONE PHARMACEUTICALS, INC.
    By:  

/s/ WILSON W. CHEUNG

      Wilson W. Cheung
      Chief Financial Officer and Senior Vice President, Finance


Exhibit Index

 

Exhibit No.

  

Description

99.1    Press release dated November 12, 2013.
99.2    Transcript of conference call dated November 12, 2013.